A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
Status:
RECRUITING
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.